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A B S T R A C T
Introduction: Detailed data on the life expectancy of patients with parkinsonism from the general population are
largely lacking. This study aimed to determine the absolute life expectancy of patients newly-diagnosed with
parkinsonism.
Methods: This study was part of the Rotterdam Study, an ongoing, population-based cohort study in the
Netherlands. We included 12,789 participants of 50 years and older, free of parkinsonism. Patients diagnosed
with parkinsonism were matched to controls on sex, birth year, dementia status, cancer status, and coronary
heart disease status. We used Gompertz regression and lifetables to estimate the remaining life expectancy per
year of age.
Results: The mean age of our study population was 65.0 (SD 9.7) years and 57.6% were women. During an
average follow-up of 12 years, 297 participants were diagnosed with parkinsonism. The mean age at parkin-
sonism diagnosis was 78.6 (SD 8.1) years. Once diagnosed with parkinsonism, the life expectancy was lower than
matched controls across a wide age range. At 65 years, the life expectancy of patients with parkinsonism was
reduced with 6.7 [95% CI: 2.4;10.7] years compared to controls. At 85, the difference in life expectancy was 1.2
[95% CI: -2.2;4.5] years compared to controls.
Conclusion: Patients diagnosed with parkinsonism have a reduced life expectancy compared to their peers in the
general population. The absolute life expectancy is mainly reduced if parkinsonism is diagnosed before the age of
70.
1. Introduction
Parkinson's disease (PD) has a considerable impact on the life of
patients and their caregivers [1,2]. PD does not only decrease quality of
life, previous studies have also shown that it reduces survival [3]. Most
survival estimates of PD originate from clinical settings [3,4], which
might differ considerably from the survival of patients with PD in the
general population.
The mortality in patients with PD is estimated to be increased ap-
proximately 1.5 times [3] and the mortality risk in patients with aty-
pical parkinsonism is even greater [4]. Studies presenting mortality
ratios are important to uncover risk factors of early death in parkin-
sonism, but they can be difficult to interpret in terms of prognosis.
Absolute life expectancy estimates are easier to share with patients and
could help care-planning. However, these estimates are underreported
in the literature [5,6].
In this study, we aimed to establish the life expectancy of
individuals diagnosed with incident parkinsonism in the general po-
pulation. Hereto, we studied the life expectancy of patients with par-
kinsonism across different ages and compared the life expectancy be-
tween men and women and PD and atypical parkinsonism. In addition,
we aimed to determine the burden of parkinsonism, expressed in the




This study was embedded within the Rotterdam Study, an ongoing,
population-based cohort study in the Netherlands. The design of the
Rotterdam study has been described previously [7]. The first cohort
started in 1990. All inhabitants of Ommoord, a district in Rotterdam,
who were 55 years and older were invited to participate and 7,983
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agreed. In 2000, the cohort was extended with 3,011 inhabitants who
had become 55 years and older or who moved into Ommoord. The
cohort was further enlarged with 3,932 participants aged 45 years and
older in 2006. The response rate over the three cohorts was 72%. At
baseline and at each four-year follow-up visit, participants underwent a
home interview and examinations at the research center.
2.2. Parkinsonism ascertainment
We used a two-phase design to identify participants with parkin-
sonism at study entry [8–10]. Participants were asked about a previous
diagnosis of parkinsonism, medication use was determined, and signs of
parkinsonism were assessed at the research center. Positively screened
participants were evaluated further for the presence of parkinsonian
symptoms by a research physician with expertise in neurological dis-
orders.
During follow-up, multiple modalities were used to evaluate par-
kinsonism. Sources of information were in-person screenings at the
research center, interviews with participants, anti-Parkinson medica-
tion use, and continuous monitoring of clinical records for terms related
to parkinsonism [8–10]. Clinical records of participants that appeared
in any of the screening modalities were assessed and case reports were
evaluated by a panel led by an experienced neurologist. Records of
possible parkinsonism cases were continuously monitored till January
1, 2015 and any changes in diagnoses over time were routinely updated
in the data.
Parkinsonism was defined as the presence of hypo-or bradykinesia
and at least one of the following cardinal signs: resting tremor, rigidity,
or postural imbalance, as observed by any physician; or a clinical di-
agnosis of parkinsonism by a neurologist or geriatrician. Parkinsonism
was subdivided into the following causes: PD, drug-induced parkin-
sonism, vascular parkinsonism, multiple system atrophy, progressive
supranuclear palsy, Lewy body dementia, parkinsonism with dementia,
corticobasal degeneration, tumor-induced parkinsonism, and un-
specified parkinsonism. PD entailed the criteria of parkinsonism, a
clinical history suggestive for PD, and at least one of the following: (a) a
clinical PD diagnosis by a neurologist or geriatrician; (b) a positive
response to dopaminergic treatment; (c) or dopamine transporter scan
findings consistent with PD. Atypical parkinsonism was defined as all
parkinsonism subtypes apart from PD.
Participants with prevalent parkinsonism, not screened for parkin-
sonism at the research center at baseline, or not providing informed
consent for follow-up were excluded from the analyses. The time at risk
for parkinsonism ended at the first of the following: diagnosis of in-
cident parkinsonism, death, loss to follow-up, or January 1, 2015.
Participants with prevalent dementia were at risk for all parkinsonism
subtypes except for PD. The time at risk for PD ended at the first of the
following: diagnosis of incident parkinsonism, incident dementia, loss
to follow-up, death, or January 1, 2015.
2.3. Mortality ascertainment
Records of the municipal administration of Rotterdam, general
practitioner files and nursing home files were continuously evaluated to
obtain information on the participants' vital status. Follow-up for
mortality was complete until May 2018. To determine the cause of
death, participants’ medical records were reviewed by trained research
assistants. The cause of death was coded by two independent research
physicians and reviewed by a medical expert in the field [7]. Cause of
death was coded according to the International Classification of Dis-
eases, 10th edition (ICD-10) [11]. Follow-up for cause-specific mor-
tality was complete until January 2015.
2.4. Covariates ascertainment
Marital status, education level, and smoking status were determined
during home-interviews. Marital status was defined as living with or
without a partner. Education was divided into four different levels:
primary education; lower or intermediate general education or lower
vocational education; intermediate vocational education or higher
general education; and higher vocational education or university.
Participants were categorized as never, former, or current smokers.
Height and weight were measured at the research center and body mass
index (BMI) was calculated as weight divided by height squared.
Diagnoses of dementia, cancer and coronary heart disease (CHD) were
ascertained with repeated screening and review of medical records [7].
2.5. Statistical analysis
Missing values of the covariates marital status (missing in 7.7%),
educational attainment (missing in 2.8%), smoking status (missing in
2.8%), and BMI (missing in 11.8%) were imputed based on age, sex, the
other covariates, and the outcomes, using the mean of five imputations.
To compare the survival and life expectancy of parkinsonism pa-
tients with control subjects, we matched patients with incident par-
kinsonism and controls on sex, birth year (maximum 2 year difference),
dementia status, cancer status, and CHD status in a one to two ratio.
The follow-up start date of the cases was set to the date of parkinsonism
diagnosis and this date was also used as the start date of the corre-
sponding controls. Kaplan Meier curves were made to estimate the
median survival in both groups. Causes of death were determined in
parkinsonism patients and controls, and proportions were calculated in
both groups. In addition, we calculated the absolute life expectancy of
patients newly diagnosed with parkinsonism and compared this to in-
dividuals without parkinsonism using life tables starting at age 55 and
ending at age 100. In this analysis, participants could undergo two
transitions: from no diagnosed parkinsonism to death and from diag-
nosed parkinsonism to death. We calculated overall age-specific in-
cidence rates for both transitions with Gompertz regression. Gompertz
regression is a parametric proportional hazard regression with a
Gompertz distribution, which is suitable for mortality data [12,13].
Subsequently, we multiplied the overall incidence rates with a weighing
factor to obtain sex-specific incidence rates. This weighing factor con-
sisted of sex-specific hazard ratios for death, obtained using Gompertz
regression, and the men to women ratio per 10-year age category. We
adjusted the hazard ratios for marital status, educational attainment,
smoking status, and BMI. Confidence intervals were calculated using
Monte Carlo simulation (parametric bootstrapping) with 10,000 runs.
The analyses were repeated for PD and atypical parkinsonism sepa-
rately.
To estimate the number of years lived with parkinsonism, we cre-
ated a multistate life table. A multistate lifetable is a demographic tool
that combines multiple health states to estimate the number of years
lived in different health states [14,15]. The multistate life table started
at age 55 and ended at age 100. We formulated three states: no diag-
nosed parkinsonism, diagnosed parkinsonism, and death. Transitions
between these states were possible from no parkinsonism to parkin-
sonism, from no parkinsonism to death, and from parkinsonism to
death. We calculated age-specific incidence rates for each of the three
transitions with Gompertz regression and calculated confidence inter-
vals again with Monte Carlo simulation.
Incidence rates and hazard ratios were calculated using Stata 15.1
and matching was performed in R 3.5.2. Life tables and the corre-
sponding confidence intervals were calculated in Excel version 2010,
using @Risk (Palisade Corporation, New York, USA) to perform Monte
Carlo simulations.
3. Results
The study population comprised 12,789 participants at risk for
parkinsonism, including 12,413 participants at risk for PD. Fig. 1 shows
the flow diagram of the study participants. The mean age of our study
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population was 65.0 (SD 9.7) years. More than half of the study par-
ticipants (57.6%) were women. At baseline, 291 participants (2.3%)
were diagnosed with dementia, 467 (3.7%) with cancer, and 809
(6.3%) with CHD (Table 1).
During an average follow-up of 12 years, 297 participants were
diagnosed with parkinsonism, including 141 participants who were
diagnosed with PD and 148 who were diagnosed with atypical par-
kinsonism (Table 2). The mean age at parkinsonism diagnosis was 78.6
(SD 8.1) years and 54.5% of incident parkinsonism patients were
women. In total, 273 parkinsonism patients, 138 PD patients, and 134
atypical parkinsonism could be matched with controls in a one to two
ratio. Of the 273 parkinsonism patients, 54 (19.8%) had prevalent de-
mentia. During follow-up, 60 parkinsonism patients (27.4% of those
without dementia at baseline) were diagnosed with dementia, com-
pared to 66 (15.1%) controls. PD patients with prevalent dementia were
excluded. During follow-up, 38 (27.5%) PD patients were diagnosed
with dementia compared to 47 (17.0%) controls. In atypical parkin-
sonism patients, 53 (39.6%) had a dementia diagnosis at baseline and
22 (27.2%) patients were diagnosed with dementia during follow-up,
compared to 27 (16.7%) controls.
The median survival in patients with parkinsonism was 4.3 [95%
confidence interval: 3.6;5.0] years, compared to a median survival of
7.5 [6.5;8.5] years in matched controls. The median survival in patients
with PD was 5.5 [4.7;7.2] years, compared to 9.4 [8.5;10.6] years in
matched controls. In patients with atypical parkinsonism, the median
survival was 3.3 [2.9;4.1] years, compared to 5.6 [4.8;6.7] years in
controls. Supplemental Fig. 1 shows the Kaplan Meier curves of patients
with parkinsonism versus matched controls, for all-cause parkinsonism,
PD, and atypical parkinsonism separately. The causes of death of pa-
tients with parkinsonism and matched controls can be found in
Supplemental Table 1.
Fig. 2 shows the estimated remaining life expectancy after parkin-
sonism diagnosis for men and women separately. The life expectancy of
patients diagnosed with parkinsonism, both men and women combined,
was reduced with 10.1 [5.6;14.3] years compared to participants
without parkinsonism at diagnosis age of 55 years. This difference was
6.7 [2.4;10.7] years at 65 years, 3.5 [-0.4;7.2] years at 75 years, and 1.2
[-2.2;4.5] years at 85 years. The life expectancy of PD patients was 10.5
[6.2;14.5] years reduced compared to participants without parkin-
sonism at diagnosis age 55 years, 7.5 [3.4;11.3] years reduced at 65
years, 4.3 [0.5;7.9] years reduced at 75 years, and 1.7 [-1.6;4.8] years
reduced at 85 years. Patients with atypical parkinsonism had a lower
life expectancy than patients with PD at every diagnosis age. The life
expectancy of patients with atypical parkinsonism was reduced with 8.7
[3.9;13.2] years compared to controls at 55 years, 5.3 [0.8;9.5] years at
65 years, 2.4 [-1.6;6.3] years at 75 years, and 0.5 [-2.9;3.9] years at 85
years. The life expectancy of parkinsonism patients was reduced more
in men than in women.
Fig. 3 shows the proportion of the remaining life expectancy lived
with parkinsonism in the entire study sample (n = 12,789). The
average proportion of the remaining life expectancy lived with par-
kinsonism ranged from 1.4% [1.0%;2.0%], corresponding to 0.4
[0.3;0.6] years, at 55 years to 8.1% [2.1%;39.2%], corresponding to
0.07 [0.0;0.3] years, at 99 years.
4. Discussion
In this population-based study we found that after diagnosis of
parkinsonism, the life expectancy of patients aged 55 years and over is
decreased compared to age, sex, and comorbidity matched controls.
The absolute life expectancy is lower in atypical parkinsonism than in
Fig. 1. Flowdiagram of study participants. The number of Parkinson's disease
patients and atypical parkinsonism patients do not add up to the total number
of parkinsonism patients (297) because Parkinson's disease patients with de-
mentia prior to diagnosis were excluded in both subgroups, but included in the
all-cause parkinsonism group. The life expectancy analyses included 273 par-
kinsonism patients, 138 Parkinson's disease patients, and 134 atypical parkin-
sonism patients because not all patients could be matched to two controls.
Table 1
Baseline characteristics.
Characteristic Total (n = 12,789)
Women, No. (%) 7,368 (57.6)
Age, mean (SD) years 65.0 (9.7)
Birth year, mean (SD) year 1933 (15)










BMI, mean (SD) kg/m2 26.9 (4.1)
Dementia, No. (%) 291 (2.3)
Cancer, No. (%) 467 (3.7)
CHD, No. (%) 809 (6.3)
Education was categorized as follows: Primary, primary education;
Lower, lower or intermediate general education or lower vocational
education; Intermediate, intermediate vocational education or higher
general education; Higher, higher vocational education or university.
Table 2
Incident parkinsonism during follow-up.
No. (%)a Age diagnosis, mean (SD) Women, No. (%)
Parkinsonism 297 (2.3) 78.6 (8.1) 162 (54.5)b
Parkinson’s disease 141 (1.1) 77.3 (7.9) 67 (47.5)c
Atypical parkinsonism 148 (1.2) 78.4 (7.7) 91 (61.5)d
a Total number at risk for parkinsonism was 12,789. Total number at risk for
Parkinson’s disease was 12,413.
b Percentage of total parkinsonism.
c Percentage of total Parkinson’s disease.
d Percentage of total atypical parkinsonism. Total number of parkinsonism
cases includes patients with dementia before Parkinson’s disease, which were
excluded in both Parkinson’s disease and atypical parkinsonism group.
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Parkinson's disease patients and the reduction in life expectancy is most
prominent if the disease is diagnosed before the age of 70. In addition,
we found that a relatively small proportion of the remaining life ex-
pectancy is lived with parkinsonism in the general population aged 55
years and over.
A limitation of our study is that death rates per year could only be
obtained using a parametric approach because of a small number of
parkinsonism patients diagnosed between the age of 50 and 60 years.
Although parkinsonism diagnoses around the age of 50 are common in
movement disorder clinics, it represents only a very small part of the
patients in the general population [16]. In addition, the follow-up for
parkinsonism was complete until January 2015, whereas the follow-up
for all-cause mortality was complete until May 2018. This difference in
follow-up time could have resulted in misclassification of patients as
controls. However, this effect is expected to be small because of the low
incidence of parkinsonism. A strength of our study is the continuous
case ascertainment with standardized criteria for parkinsonism. This
approach diminished the possibility of time-trends in diagnoses and
enabled us to study the life expectancy directly from the moment of
parkinsonism diagnosis. Continuous follow-up of clinical records al-
lowed us to update the diagnosis if this changed over time, which in-
creases the accuracy of diagnosis, although the diagnosis is not as ac-
curate as pathologic examination [17]. Our population-based design
made it possible to study both patients seen by a medical specialist and
those who presented only at the general practitioner, resulting in a good
representation of all parkinsonism cases in the general population.
Furthermore, we matched patients with controls not only on sex and
birth year, but also on dementia, cancer, and CHD status. Finally, we
showed robustness of our results by presenting both the commonly-
described Kaplan Meier estimates and the absolute life expectancy es-
timates, which showed comparable results.
The burden of parkinsonism has been investigated previously in
Fig. 2. Estimated remaining life expectancy for all-cause parkinsonism, Parkinson's disease and atypical parkinsonism after diagnosis. Panels A and B represent the
remaining life expectancy of individuals with (n = 273) and without (n = 546) incident all-cause parkinsonism per five years for men (A) and women (B) separately.
Panels C and D represent the remaining life expectancy of individuals with (n = 138) and without (n = 276) incident Parkinson's disease per five years for men (C)
and women (D) separately. Panels E and F represent the remaining life expectancy of individuals with (n = 134) and without (n = 268) incident atypical
parkinsonism per five years for men (E) and women (F) separately. The error bars show the 95% confidence intervals.
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terms of disability-adjusted life-years and costs [18,19]. However, our
study is novel in expressing the burden in the number of years a person
in the general population lives with parkinsonism. Our results show
that from 55 to 99 years of age 1.4%–8.1% of the remaining life ex-
pectancy is lived with parkinsonism. This estimate is important con-
sidering the impact parkinsonism has on quality of life [20–23].
Nevertheless, the described proportions are relatively small and corre-
spond to a low number of absolute years lived with parkinsonism,
which can be explained in three ways. First, the proportion of the re-
maining life expectancy lived with parkinsonism is influenced by the
low incidence of parkinsonism in the general population [24]. Second,
PD and several other parkinsonism subtypes have a prediagnostic phase
that starts years before clinical diagnosis [25], which is not taken into
account when looking at parkinsonism from the moment of diagnosis.
Individuals in the general population might thus live more years with
disease than reported in this study. Third, the proportion of the re-
maining life expectancy lived with parkinsonism is influenced by the
survival after diagnosis, which is decreased.
The survival of parkinsonism patients has often been studied by the
relative increase in mortality risk [3,26,27]. Previous studies have de-
scribed an approximately 1.5 times increased mortality risk in patients
with PD [3] and an even greater risk in other parkinsonism subtypes
[4]. Although these risks give an indication on survival, these estimates
are difficult to translate to patients. Absolute life expectancy estimates
are easier to interpret and can help patients to better understand their
prognosis.
Few previous studies have reported the absolute life expectancy of
patients with parkinsonism [4–6,28], and even fewer have shown the
course of the life expectancy compared to the general population [5,6].
Our results are consistent with the findings of Ishihara et al. who cal-
culated the life expectancy of patients with PD from previously reported
standardized mortality ratios and compared this to the life expectancy
in the United Kingdom [5]. The study of Savica et al. found a one year
difference in age at death for PD patients compared to controls at a
diagnosis age around 75 [4]. This difference is smaller than the dif-
ference of 4.3 years that we found for PD compared to controls at age
75. However, our confidence interval around this difference was wide
[95% confidence interval: 0.5;7.9] and overlaps with their estimate. In
addition, the study of Savica et al. showed that the life expectancy was
mainly reduced in MSA and DLB patients. We also found a lower life
expectancy in atypical parkinsonism patients than in PD patients, but
the difference with controls was smaller than in PD. This can be ex-
plained by the one-year higher mean age of patients with atypical
parkinsonism and the inclusion of patients with prevalent dementia in
this group. Importantly, our group of atypical parkinsonism patients
includes a wide variety of parkinsonism subtypes, including drug-in-
duced and vascular parkinsonism, and might thus represent a different
patient population than participants of the study of Savica et al.
In our study, PD patients were free of dementia at the time of PD
diagnosis because the cases were ascertained according to the old cri-
teria for diagnosing PD [29]. Still, we found a considerable negative
effect of PD on the remaining life expectancy in both men and women.
Our findings differ in this aspect from the results of several previous
studies that did not describe an increased mortality risk in cognitively
normal patients [6,27]. However, we did not rule out mild cognitive
impairment in our study. The increased mortality risk could be partly
attributed to the increased risk of developing dementia after PD, as
suggested by a previous study within the Rotterdam Study [30] and also
supported by our data showing that PD patients developed dementia
more frequently than controls.
A meta-analysis by Macleod et al. indicated that most studies found
increasing age at diagnosis to predict mortality risk in PD [3]. When
looking at the absolute life expectancies, however, we find that the
reduction in life expectancy is largest before the age of 70. This result is
in accordance with previous studies presenting absolute life ex-
pectancies [5,6]. We found a larger difference in life expectancy be-
tween parkinsonism patients, both PD and atypical parkinsonism, and
controls in men than in women. This different prognosis of PD in men
and women was also found by some previous studies, but not confirmed
by the meta-analysis of Macleod et al. [3]. The effect of sex on the
remaining life expectancy of different parkinsonism subtypes has been
limitedly studied so far. Therefore, future studies are warranted to
provide further insight into the sex-differences in the life expectancy of
parkinsonism subtypes.
5. Conclusions
In conclusion, our study showed that the absolute life expectancy of
individuals diagnosed with parkinsonism is reduced compared to in-
dividuals without parkinsonism, especially if disease is diagnosed be-
fore the age of 70. Future studies are warranted to investigate sex-dif-
ferences in the life expectancy of rarer causes of parkinsonism.
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